Vnitr Lek 2006, 52(4):302-303

Hypertrofická kardiomyopatie - názory na současné léčebné postupy - editorial

J. Vojáček
I. interní klinika Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Jan Vojáček, DrSc., FESC

Received: March 19, 2006; Published: April 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vojáček J. Hypertrofická kardiomyopatie - názory na současné léčebné postupy - editorial. Vnitr Lek. 2006;52(4):302-303.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Faber L, Meissner A, Ziemssen P et al. Percutaneous transluminal septal myocardial ablation for HOCM: Long-term follow-up in the first series of 25 patients. Heart 2000; 83: 326-331. Go to original source... Go to PubMed...
    2. Gadler F, Linde C, Daubert C et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year follow-up. PIC study group. Pacing in cardiomyopathy. Eur Heart J 1999; 20: 1044-1050. Go to original source... Go to PubMed...
    3. Hlaváček K, Horák D, Oą»ádal P et al. Transkoronární ablace septální hypertrofie (TASH) u nemocného s hypertrofickou obstrukční kardiomyopatií (HOCM). Abstrakt. Poster, VI. výroční sjezd České kardiologické společnosti, Brno, 24.-27. května 1998.
    4. Krejčí J, Groch L, Meluzín J et al. Nefarmakologická léčba hypertrofické obstrukční kardiomyopatie - srovnání výsledků metodami perkutánní transluminální septální ablace a dvoudutinové stimulace. Vnitř Lék 2006; 52: 312-320.
    5. Kuhn H, Gietzen F, Leuner C et al. Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997; 18: 846-851. Go to original source... Go to PubMed...
    6. Kuhn H, Seggewiss H, Gietzen FH et al. Catheter-based therapy for hypertrophic obstructive cardiomyopathy: First in-hospital outcome analysis of the German TASH Registry. Z Kardiol 2004; 93: 23-31. Go to original source... Go to PubMed...
    7. Kvasnička J, Gajdoąová I, Tauchman M et al. Léčba hypertrofické obstruktivní kardiomyopatie: DDD stimulace, verapamil nebo obojí? Abstrakt. Kardiologické dny Praha, 18. 11. 1993.
    8. Maron BJ, McKenna WJ, Danielson GK et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42: 1687-1713. Go to original source... Go to PubMed...
    9. McDonald K, McWilliams E, O'Keeffe B et al. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J 1988; 9: 893-898. Go to original source... Go to PubMed...
    10. Morrow AG, Reitz BA, Epstein SE et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975; 52: 88-102. Go to original source... Go to PubMed...
    11. Sechtem U, Mahrholdt H, Hager S et al. New non-invasive approaches for the diagnosis of cardiomyopathy: magnetic resonance imaging. Ernst Schering Res Found Workshop 2006; 55: 261-285. Go to original source... Go to PubMed...
    12. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.